華大基因(300676.SZ):子公司中標5.13億元孕婦無創產前基因免費篩查項目檢測服務項目
格隆匯12月25日丨華大基因(300676.SZ)公佈,公司控股子公司深圳華大臨牀檢驗中心(深圳臨檢)近日收到河北省公共資源交易中心下發的《中標通知書》,通知書確認深圳臨檢為河北省衞生健康委員會2021-2023年度全省孕婦無創產前基因免費篩查項目檢測服務項目(採購編號:Z1300002026841301)的中標單位。此次中標項目預算金額為5.1264億元,正式合同約定金額將不超過預算金額。
出生缺陷嚴重影響兒童健康和家庭幸福,造成沉重的社會經濟負擔。預防和避免出生缺陷是提高出生人口素質、推進健康中國建設的重要舉措。開展孕婦無創產前基因檢測服務,是預防為主、防治結合的健康策略體現,有利於實現唐氏綜合徵等疾病的早發現、早診斷、早干預,精準防控出生缺陷。
在生育健康領域,公司持續開展相關的基礎研究和臨牀應用服務,具備多組學的技術平台,涵蓋出生缺陷三級防控的豐富產品線,旨在全面助力出生缺陷防控,提高兒童健康水平。若此次中標項目後續順利實施,有利於讓精準醫學惠及更多家庭,對公司未來經營業績產生一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.